As MM patients with plasma cell-targeting therapies (anti-CD38 and anti-B-Cell-Maturation-Antigen [BCMA] mAbs) showed very weak primary vaccine responses [5], the investigation of Ab kinetics and specific B memory cell development during booster vaccinations over a follow-up period of two years is of high interest. The gene discussed is CD38; the disease is Miyoshi myopathy.